Flu Shot Reminder
Summary: A good time to get the annual shots is October or November, before the flu season begins.
Flu Shot Reminder
Summary: A good time to get the annual shots is October or November, before the flu season begins.
by John S. James Summary: A Philadelphia program for people with a mental health diagnosis who are HIV-positive has won national recognition. We interviewed its founder for ideas and approaches others can use. CLR entrance CLR near entrance CLR living room —————————————- The unique Community Living Room in Philadelphia was selected as a model adult mental health day program, both locally and nationally in the U.S. It serves people with a mental health diagnosis who are HIV-positive. Jeff Hoeltzel, M.Sc. and a licensed psychiatric rehabilitation practitioner, built the CLR during the almost 12 years he directed it. He will be leaving in February 2007, and the staff he trained will continue the organization. AIDS Treatment News interviewed Jeff on January 10, 2007. ***** AIDS Treatment News: Could you outline the guiding philosophy of the Community Living Room, how it started, and the recognition it has received in the mental health field? Jeff Hoeltzel: The Community Living Room is the first thoroughly community-based mental health HIV program in the United States — meaning that it is not part of a hospital or university providing mental health services, or within an HIV agency with a few counselors. The whole focus here is on the mental health HIV client. CLR was started with a grant from the U.S. National Institute of Mental Health to the city of Philadelphia in 1995. The grant was awarded to 11 cities in the United States in the first go-around, to look at whether there was a need for specialized mental health services for people with HIV — or should we put these clients into the regular public mental health system. In Philadelphia this project was looking to serve low-income people, and those who often don’t seek out services. In the other 10 cities the programs were attached to institutions such as universities or hospitals. Philadelphia did something different, and asked COMHAR (https://www.comhar.org) to set up a freestanding community-based service. … How CLR Works: The Three Pillars We wanted to do a couple things differently than traditional mental health services. We needed to engage people who are very difficult to engage, because many times they are on the outskirts of the society, sometimes because of stigma of HIV, sometimes mental health, or sexuality issues; often they are rejected by families and social circles. I decided not to go any traditional route, but to reach out, to deal with their pain but also their joy and their possibilities. After first coming here I talked with every client I could individually, and discovered how isolated people felt, how alone they had felt beforehand, and how they thought they were going through things uniquely. So one of the pillars was how to help people build relationships, connect, and network — that had to be one of the major goals we had in this program. The second pillar is achievement. People with mental health issues often have what we call in psychiatry learned helplessness; they feel that they are not able to do anything. They had HIV added onto that, and it was before protease inhibitors, so people had the specter of death looming, and many had given up. I wanted accomplishment to be the 2nd pillar, so that people could achieve and get rewards for doing so, both internally and externally. We built on a theory of successive successes — that no matter how small the success we could build on it, but let’s help people find something that in a couple weeks they could achieve. The third pillar is to build empowerment. The first step in empowerment is knowledge. So we want the Community Living Room to be a place where people can come in and share knowledge, and members (clients) can share knowledge with each other. But there are many smart people who are not empowered. You cannot empower people, only provide the tools so they can empower themselves. Many people needed the skills to use their knowledge to their advantage. So we had to design services that also taught skills. But many skillful people are still not empowered. So we had to help instill motivation to use the skills and knowledge to their benefit. Two other principles evolved..: (1) We needed a program not based only on problems. Psychiatry is so problem-oriented that people are not aware of strengths and wellness. When I would do an intake, people could often talk for a long time on their problems. But when I asked them to tell me about their talents and strengths, how quiet they were! They were so quiet, yet they all had talents and strengths. So I wanted to do a more holistic program — one that involved peoples’ talents, and the creative arts, and presented different ways they could get involved in HIV and other treatment. On complementary therapies, I may not agree that all of them are equally important (herbal therapy, aromatherapy, massage, among many others) but we wanted to present this approach. We wanted to have art, music, dance, writing, and drama — because people are more than HIV, more than mental health, more than their labels. So we developed a holistic approach. (2) The second addition that became like the fifth pillar was community integration. People come here, and we work hard to make the space look attractive, inviting, and engaging. But I didn’t want a sanctuary from the real world; I wanted windows to look right out on Philadelphia streets. Those same streets that held difficulties before also hold promise here in Philadelphia. I wanted a program that sent people out into the world to live. We’re the Community Living Room, and I wanted to highlight living in the world, not just in the program. So we provide opportunities, and help people find different niches in the world than they ever found before — sometimes to find a job, sometimes volunteer work, and sometimes committees. We have almost 25 clients on committees in the city, from mental health, to HIV, to
by John S. James Summary: Our new toll-free editorial and business number is 1-800-804-8845 — Monday through Friday 2 p.m. to 5 p.m. Eastern time (11 a.m. to 2 p.m. Pacific time), or leave a message. This number is for editorial and business calls; please do not list it as a hotline. —————————————- We are changing our toll-free editorial and business number to 1-800-804-8845. This number, effective now, will forward anywhere, so you can more easily reach a person during our new business hours, currently 2 p.m. to 5 p.m. Eastern time Monday through Friday (11 a.m. to 2 p.m. Pacific time). Voicemail messages at other times will be emailed to us immediately. Please delete the old numbers (800-treat-1-2 or 800-873-2812, and the -3776 number) from all listings. We will have forwarding or a referral message there for the rest of 2007 at least, but due to spam calls the new number may not be announced on those lines. So make a note of it — or check on any page of this or any later issue of AIDS Treatment News. Our toll-free number is not a hotline, as we are not set up to handle hotline calls. It is for editorial calls about what AIDS Treatment News has published (or should publish), or for business such as billing or change of address. See hotline information below. —————————————- Also see our AIDS Treatment News Daily Alerts, updated every day at www.aidsnews.org/now Return to home page: www.aidsnews.org Free subscription to AIDS Treatment News announcements online: send a blank email to subscribe@aidsnews.org — and reply to the email request from Yahoo to confirm your subscription. You will receive about five emails or fewer per month and can leave the list at any time. Or just visit www.aidsnews.org to read the articles — no subscription or registration required. [Note: subscriptions to AIDS Treatment News Daily Alerts are handled separately at www.aidsnews.org/now] Copyright 2007 by John S. James. We prefer that you link to www.aidsnews.org or a specific article — no permission required. Otherwise permission is granted for nonprofit use. Please check with us (aidsnews@aidsnews.org) before copying articles more than a year old.
Summary: The Fair Pricing Coalition and others are collecting signatures until this important Merck drug (the first integrase inhibitor) is approved and launched. —————————————- The Fair Pricing Coalition is asking Merck to price its new and very important integrase inhibitor at a level everyone can live with. The letter is seeking organization and individual signers until the official launch of the drug, when the price will be announced. “A new HIV drug produced by Merck is about to be approved by the Food & Drug Administration in early October. While this is great news, especially for people who have developed resistance to existing therapies, the pricing of this treatment will have a major impact on the various publicly funded programs like Medicaid, Medicare, and the AIDS Drug Assistance Program, all of which are already straining at the breaking point. “Please join the Fair Pricing Coalition by signing onto the following statement to Merck. …” For the text of the letter and instructions for signing, visit https://www.aidsnews.org/now/2007/09/pricing-of-new-hiv-drug-threatens.html —————————————- Also see our AIDS Treatment News Daily Alerts, updated every day at www.aidsnews.org/now Return to home page: www.aidsnews.org Free subscription to AIDS Treatment News announcements online: send a blank email to subscribe@aidsnews.org — and reply to the email request from Yahoo to confirm your subscription. You will receive about five emails or fewer per month and can leave the list at any time. Or just visit www.aidsnews.org to read the articles — no subscription or registration required. [Note: subscriptions to AIDS Treatment News Daily Alerts are handled separately at www.aidsnews.org/now] Copyright 2007 by John S. James. We prefer that you link to www.aidsnews.org or a specific article — no permission required. Otherwise permission is granted for nonprofit use. Please check with us (aidsnews@aidsnews.org) before copying articles more than a year old.
by John S. James Summary: How news feeds can advance biomedical research — as well as helping people follow specialized news. —————————————- A great challenge today is to help people find the key information they want and need, in the tsunami of new material that keeps coming out. Search engines cannot replace human judgment for alerting people to opportunities they did not know about at all, and therefore did not search for. And the same news feeds for specialists could help research as well. Large AIDS conferences have thousands of abstracts presented in a few days; almost no one reads and understands all of them. Leaders and core groups focus on a few — so crucial but unusual discoveries may not get attention. A number of specialists scanning the conference presentations will catch some of these and alert an interested community immediately. There are already AIDS news feeds, for example the Kaiser Daily HIV/AIDS Report, https://www.kaisernetwork.org/Daily_reports/rep_hiv.cfm but we need many more, and the Kaiser service is labor intensive and probably expensive to maintain. An easier system would allow different experts to develop a great variety of possible news feeds — such as vaccines, AIDS-related cancers, treatment news for resource-limited settings, or basic-science issues. Anyone, anywhere can set up a news feed like ours, completely free if they already have online access. For science and medicine we suggest using https://www.connotea.org (which is specialized for these fields) — and for other subjects, we suggest https://del.icio.us (which is simpler; this writer used it to collect links for https://www.peacephilly.org). You can include almost any news story or other public Web site on the list that you create. (Alternatively you could use a blog — but the “social bookmarking” services like Connotea and del.icio.us are easier because it takes only seconds to add a new Web page to your list, helping to keep it up to date.) You can easily provide an important news service worldwide, in any specialized field where you have an interest and background, and need to keep up with new developments anyway. For AIDS information, we think the next step will be news feeds by small groups, maybe two to ten people or more — or highly specialized feeds by individuals. Meanwhile see our experiment at www.aidsnews.org/now. —————————————- Return to home page: www.aidsnews.org Free subscription to announcements online: send a blank email to subscribe@aidsnews.org — and reply to the email request from Yahoo to confirm your subscription. You will receive about five emails or fewer per month and can leave the list at any time. Or just visit www.aidsnews.org to read the articles — no subscription or registration required. Copyright 2007 by John S. James. We prefer that you link to www.aidsnews.org or a specific article — no permission required. Otherwise permission is granted for nonprofit use. Please check with us (aidsnews@aidsnews.org) before copying articles more than a year old.
Summary: The inventor of the machine used to count T-cells, collect stem cells, and measure or collect many other rare cells was awarded the prestigious Kyoto Prize for advanced technology, at a ceremony in Japan. —————————————- Leonard Herzenberg, Ph.D., professor of genetics at Stanford University, received the Kyoto Prize, often called the Japanese version of the Nobel Prize, for developing the fluorescence-activated cell sorter (FACS), the machine that measures patients’ CD4 cell counts, and many other cells for research. The same machine can physically sort rare blood cells such as stem cells into a separate compartment, where the living cells can be cultured for research or treatment. The dean of Stanford’s School of Medicine called FACS “one of the most important medical devices ever developed.” Dr. Herzenberg received the prize November 10, 2006, at a ceremony in Japan. “I only wish it were possible to be shared with my wife and lifelong colleague, Leonore Herzenberg,” he said. Leonore Herzenberg, Ph.D., is also professor of genetics at Stanford. The Kyoto Prize, for contributions to humanity as well as to science, is awarded to one individual in each research team. The Herzenbergs may be familiar to readers of AIDS Treatment News for their studies of NAC (n-acetylcysteine) to restore antioxidant protection by correcting glutathione deficiency in HIV disease. NAC is also being studied in treatment of many other conditions, from bacterial meningitis to cocaine dependency. For more information, see: https://news-service.stanford.edu/news/2006/november15/med-kyoto-111506.html https://news-service.stanford.edu/news/2006/june14/herz-061406.html and https://siarchives.si.edu/research/videohistory_catalog9554.html (Note: the third link is to the Smithsonian Institution, describing its collection of videotapes on the development of FACS.) —————————————- Return to home page: www.aidsnews.org Free subscription to announcements online: send a blank email to subscribe@aidsnews.org — and reply to the email request from Yahoo to confirm your subscription. You will receive about five emails or fewer per month and can leave the list at any time. Or just visit www.aidsnews.org to read the articles — no subscription or registration required. Copyright 2007 by John S. James. We prefer that you link to www.aidsnews.org or a specific article — no permission required. Otherwise permission is granted for nonprofit use. Please check with us (aidsnews@aidsnews.org) before copying articles more than a year old.
by John S. James Summary: During the first two weeks after release, prisoners in Washington State had 129 times the death rate from drug overdose, compared to other state residents — probably because they did not know how much less drug they could tolerate, after taking little or none of it prison. Cardiovascular disease, homicide, suicide, cancer, and traffic accidents also caused excessive deaths. —————————————- A study of over 30,000 recently released prisoners (regardless of HIV) in Washington State found that they had a 3.5 times increased risk of death after release than other residents of the state, much higher than the death rate in prison. [1] The first two weeks after release were particularly dangerous, with a risk of death 12.7 times that of the general population. The three leading causes of death were drug overdose (103 deaths, a quarter of all the deaths), cardiovascular disease (56 deaths, 10 of them from a heart attack), and homicide (54 deaths). Suicide, cancer, and traffic accidents also caused many deaths. The risk of death from overdose during the two weeks after release was 129 times the risk in the general population. The article noted that death might have occurred because prisoners lost their tolerance to the drugs due to relative abstinence in prison (so doses they took before prison might kill them when they got out, because then they were not used to such high doses). “Possible interventions after release include providing intensive case management during the period immediately following release and improving access to and continuity of medical and mental health care.” [1] Comment Even when funding for proper prisoner re-entry cannot be found, the huge overdose risk shortly after release might be reduced by educating drug cultures. Explain that people can die after taking a customary high dose of cocaine, meth or other stimulants, heroin, other narcotics (including methadone, responsible for 18 deaths in this study), tricyclic antidepressants (Elavil and many others), and some other prescription drugs, after being off of the drug for a time. Interaction with HIV drugs (especially ritonavir, including the smaller combination doses) can cause severe overdose of some drugs. Marijuana (not mentioned in this research report) is different, as no one has ever been known to have died from an overdose. [2] In contrast, a large overdose of water can be fatal — a serious risk when people drink enormous amounts trying to pass a drug test. References 1. Binswanger IA, Stern MF, Deyo RA and others. Release from prison — A high risk of death for former inmates. New England Journal of Medicine. January 11, 2007; volume 356, number 2, pages 157-165, https://content.nejm.org/cgi/content/abstract/356/2/157 (Note: the Feb. 1 correction in Journal does not affect the AIDS Treatment News article.) 2. Editorial. Comparing cannabis with tobacco — again. British Medical Journal, September 20, 2003, https://www.bmj.com/cgi/content/full/327/7416/635 —————————————- Return to home page: www.aidsnews.org Free subscription to announcements online: send a blank email to subscribe@aidsnews.org — and reply to the email request from Yahoo to confirm your subscription. You will receive about five emails or fewer per month and can leave the list at any time. Or just visit www.aidsnews.org to read the articles — no subscription or registration required. Copyright 2007 by John S. James. We prefer that you link to www.aidsnews.org or a specific article — no permission required. Otherwise permission is granted for nonprofit use. Please check with us (aidsnews@aidsnews.org) before copying articles more than a year old.
Summary: The FDA added new drug-interaction warnings to the prescribing information for Sustiva (efavirenz). —————————————- On January 31 the FDA announced that the Sustiva (efavirenz) package insert had been changed “to include drug-drug interaction information regarding coadministration of efavirenz with rifampin, diltiazem, itraconazole, voriconazole, atorvastatin, pravastatin, simvastatin, pimozide and bepridil.” The complete list of changes is at https://www.fda.gov/oashi/aids/listserve/listserve2007.html#13107 And the new version for patients, and also one for physicians, is at https://www.sustiva.com (click “Patient Information” to download a PDF file — or click “Full U.S. Prescribing Information” and change the ending of the file name from .pl to .pdf is necessary). —————————————- Return to home page: www.aidsnews.org Free subscription to announcements online: send a blank email to subscribe@aidsnews.org — and reply to the email request from Yahoo to confirm your subscription. You will receive about five emails or fewer per month and can leave the list at any time. Or just visit www.aidsnews.org to read the articles — no subscription or registration required. Copyright 2007 by John S. James. We prefer that you link to www.aidsnews.org or a specific article — no permission required. Otherwise permission is granted for nonprofit use. Please check with us (aidsnews@aidsnews.org) before copying articles more than a year old.
Summary: The FDA changed the FUZEON prescribing information to help avoid this common and unpleasant side effect of the drug. —————————————- On January 31 the FDA announced that the FUZEON (enfuvirtide) package insert had been changed to include precautions to avoid injection-site reactions, either using a needle, or the Biojector(r) 2000 needlefree injection system. For example, here is one place where changes were made (this is from the new version): “Patients and caregivers should be instructed on the preferred anatomical sites for administration (upper arm, abdomen, anterior thigh). FUZEON should not be injected near any anatomical areas where large nerves course close to the skin, such as near the elbow, knee, groin or the inferior or medial sections of the buttocks, skin abnormalities, including directly over a blood vessel, into moles, scar tissue, bruises, or near the navel, surgical scars, tattoos or burn sites.” The changes are at: https://www.fda.gov/oashi/aids/listserve/listserve2007.html#013007 And the complete revised prescribing information is at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=2705 —————————————- Return to home page: www.aidsnews.org Free subscription to announcements online: send a blank email to subscribe@aidsnews.org — and reply to the email request from Yahoo to confirm your subscription. You will receive about five emails or fewer per month and can leave the list at any time. Or just visit www.aidsnews.org to read the articles — no subscription or registration required. Copyright 2007 by John S. James. We prefer that you link to www.aidsnews.org or a specific article — no permission required. Otherwise permission is granted for nonprofit use. Please check with us (aidsnews@aidsnews.org) before copying articles more than a year old.
Summary: Quick reference for telephone information. —————————————- For AIDS information (such as where to get tested, transmission, symptoms, news stories, or local AIDS organizations), try 1-800-CDC-INFO (1-800-232-4636), toll-free 24 hours a day in English or Spanish; when asked, select option ‘1’ to reach a person for health information. Trained operators can answer many questions using an extensive database. Usually you can reach an operator immediately, unless many people are calling due recent media coverage of AIDS or other health concerns. To find a local AIDS specialist physician, try the “Find a Provider in Your Area” link at the American Academy of HIV Medicine, https://www.aahivm.org For an HIV and AIDS treatment hotline, try Project Inform, 800-822-7422, 10 a.m. – 4 p.m. Pacific time Monday through Friday. You may need to wait as the volunteers are helping other callers. For many more AIDS hotlines, search for “HIV hotlines” (preferably with the quotation marks) on Google or another search engine. —————————————- Also see our AIDS Treatment News Daily Alerts, updated every day at www.aidsnews.org/now Return to home page: www.aidsnews.org Free subscription to AIDS Treatment News announcements online: send a blank email to subscribe@aidsnews.org — and reply to the email request from Yahoo to confirm your subscription. You will receive about five emails or fewer per month and can leave the list at any time. Or just visit www.aidsnews.org to read the articles — no subscription or registration required. [Note: subscriptions to AIDS Treatment News Daily Alerts are handled separately at www.aidsnews.org/now] Copyright 2007 by John S. James. We prefer that you link to www.aidsnews.org or a specific article — no permission required. Otherwise permission is granted for nonprofit use. Please check with us (aidsnews@aidsnews.org) before copying articles more than a year old.